InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
19 Marzo 2024 - 5:30AM
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering
anti-inflammatory therapeutics by targeting the complement system,
today announced that it will host a conference call this Thursday,
March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s
anticipated development plans for INF904, InflaRx’s orally
available C5aR inhibitor with best-in-class potential. The Company
will also publish its financial and operating results for the
fourth quarter and full year 2023 on March 21, 2024, in advance of
the call.
To participate in the conference call,
participants may pre-register here and will receive a dedicated
link and dial-in details to easily and quickly access the call. A
replay will be available on the InflaRx website in the Investors –
Events & Presentations section after the live conference call
has concluded.
About InflaRx
InflaRx GmbH (Germany) and InflaRx
Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx
N.V. (together, InflaRx). InflaRx (Nasdaq: IFRX) is a biotechnology
company pioneering anti-inflammatory therapeutics by applying its
proprietary anti-C5a and anti-C5aR technologies to discover,
develop and commercialize highly potent and specific inhibitors of
the complement activation factor C5a and its receptor C5aR. C5a is
a powerful inflammatory mediator involved in the progression of a
wide variety of inflammatory diseases. InflaRx’s lead product
candidate, vilobelimab, is a novel, intravenously delivered,
first-in-class, anti-C5a monoclonal antibody that selectively binds
to free C5a and has demonstrated disease-modifying clinical
activity and tolerability in multiple clinical studies in different
indications. The Company is also developing INF904, an orally
administered small molecule inhibitor of C5a-induced signaling via
the receptor C5aR. InflaRx was founded in 2007, and the group has
offices and subsidiaries in Jena and Munich, Germany, as well as
Ann Arbor, MI, USA. For further information, please visit
www.inflarx.com.
Contacts
InflaRx N.V. |
MC Services AG |
Jan Medina, CFAVice President, Head of Investor RelationsEmail:
IR@inflarx.de |
Katja Arnold, Laurie Doyle, Dr. Regina LutzEmail:
inflarx@mc-services.eu Europe: +49 89-210 2280U.S.:
+1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “estimate,” “believe,”
“predict,” “potential” or “continue,” among others. Forward-looking
statements appear in a number of places throughout this release and
may include statements regarding our intentions, beliefs,
projections, outlook, analyses and current expectations concerning,
among other things, the receptiveness of Gohibic (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals and
related treatment recommendations by medical/healthcare institutes
and other third-party organizations, our ability to successfully
commercialize and the receptiveness of Gohibic (vilobelimab) as a
treatment for COVID-19 by COVID-19 patients and U.S. hospitals or
our other product candidates; our expectations regarding the size
of the patient populations for, market opportunity for, coverage
and reimbursement for, estimated returns and return accruals for,
and clinical utility of Gohibic (vilobelimab) in its approved or
authorized indication or for vilobelimab and any other product
candidates, under an Emergency Use Authorization and in the future
if approved for commercial use in the United States or elsewhere;
our ability to successfully implement The InflaRx Commitment
Program, the success of our future clinical trials for
vilobelimab’s treatment of COVID-19 and other debilitating or
life-threatening inflammatory indications, including pyoderma
gangrenosum, and any other product candidates, including INF904,
and whether such clinical results will reflect results seen in
previously conducted pre-clinical studies and clinical trials; the
timing, progress and results of pre-clinical studies and clinical
trials of our product candidates and statements regarding the
timing of initiation and completion of studies or trials and
related preparatory work, the period during which the results of
the trials will become available, the costs of such trials and our
research and development programs generally; our interactions with
regulators regarding the results of clinical trials and potential
regulatory approval pathways, including related to our Marketing
Authorization Application submission for vilobelimab and our
biologics license application submission for Gohibic (vilobelimab),
and our ability to obtain and maintain full regulatory approval of
vilobelimab or Gohibic (vilobelimab) for any indication; whether
the U.S. Food and Drug Administration, the European Medicines
Agency or any comparable foreign regulatory authority will accept
or agree with the number, design, size, conduct or implementation
of our clinical trials, including any proposed primary or secondary
endpoints for such trials; our expectations regarding the scope of
any approved indication for vilobelimab; our ability to leverage
our proprietary anti-C5a and C5aR technologies to discover and
develop therapies to treat complement-mediated autoimmune and
inflammatory diseases; our ability to protect, maintain and enforce
our intellectual property protection for vilobelimab and any other
product candidates, and the scope of such protection; our
manufacturing capabilities and strategy, including the scalability
and cost of our manufacturing methods and processes and the
optimization of our manufacturing methods and processes, and our
ability to continue to rely on our existing third-party
manufacturers and our ability to engage additional third-party
manufacturers for our planned future clinical trials and for
commercial supply of vilobelimab and for the finished product
Gohibic (vilobelimab); our estimates of our expenses, ongoing
losses, future revenue, capital requirements and our needs for or
ability to obtain additional financing; our ability to defend
against liability claims resulting from the testing of our product
candidates in the clinic or, if approved, any commercial sales; if
any of our product candidates obtain regulatory approval, our
ability to comply with and satisfy ongoing obligations and
continued regulatory overview; our ability to comply with enacted
and future legislation in seeking marketing approval and
commercialization; our future growth and ability to compete, which
depends on our retaining key personnel and recruiting additional
qualified personnel; and our competitive position and the
development of and projections relating to our competitors in the
development of C5a and C5aR inhibitors or our industry; and the
risks, uncertainties and other factors described under the heading
“Risk Factors” in our periodic filings with the U.S. Securities and
Exchange Commission. These statements speak only as of the date of
this press release and involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
InflaRx NV (NASDAQ:IFRX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
InflaRx NV (NASDAQ:IFRX)
Gráfica de Acción Histórica
De May 2023 a May 2024